ILiAD Biotechnologies
Biotechnology company focused on the prevention and treatment of disease caused by bordetella pertussis.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD233—350m (Dealroom.co estimates Sep 2022.)
Weston Florida (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $640k | Debt | |
| N/A | $550k | Seed | |
| N/A | $8.0m | Seed | |
| N/A | $680k | Angel | |
$20.0m | Early VC | ||
$4.3m | Late VC | ||
$23.5m | Late VC | ||
* | $1.0m | Grant | |
* | $42.8m | Series D | |
| Total Funding | CAD137m | ||
Related Content
Recent News about ILiAD Biotechnologies
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.